The Long-Term Care Data Cooperative is a provider-led database of de-identified nursing home medical records, built by the American Health Care Association and National Center for Assisted Living (AHCA/NCAL) with Brown University and Exponent, Inc., and funded by the National Institute on Aging. It matters to families following dementia research because it gives scientists day-to-day clinical detail on residents with Alzheimer's disease and related dementias that older data sources never captured, according to AHCA's overview of the Cooperative. The Cooperative pulls records directly from the electronic health record systems nursing homes already use, and facilities join at no cost, which has let it grow without the expense that usually limits research databases, per AHCA's FAQ on the Cooperative. For readers managing dementia care, this matters because it determines what kinds of studies the data can actually support, and where those studies still fall short.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What data goes into the Cooperative, and why that matters for dementia studies
- How representative is the data, and what are its limits?
- What dementia-specific research is actually using this data?
- Can researchers connect this to other medical records, and what does that enable?
- What this means if you're tracking a loved one's dementia care
What data goes into the Cooperative, and why that matters for dementia studies
The Cooperative receives records straight from the three largest nursing-home electronic medical record vendors — American HealthTech, MatrixCare, and PointClickCare — so participating facilities don't have to build any special reporting process, according to AHCA's FAQ. Because enrollment is free, cost isn't a barrier that keeps smaller or rural facilities out.
A 2026 analysis in the Journal of the American Geriatrics Society found that most participating facilities consistently record vital signs, medication administration, blood glucose readings, and immunizations — clinical detail that simply doesn't exist in Medicare claims data or the Minimum Data Set assessments researchers have relied on until now, per the IMPACT Collaboratory's summary of that study. For a family trying to understand how a loved one's dementia medications interact with other prescriptions, this is the layer of detail that claims-based research has historically missed.
How representative is the data, and what are its limits?
The same 2026 JAGS analysis compared residents captured in the Cooperative against the national nursing home population and found only small, statistically significant demographic and clinical differences, which supports using the dataset for conclusions that apply broadly rather than just to the facilities involved, according to the IMPACT Collaboratory. That's a meaningful validation step for any dataset aiming to inform national dementia-care practice. Still, the data have a real boundary. Coverage comes only from facilities that use one of the three partnered EMR systems and that chose to enroll — it isn't a random or complete sample of every U.S.
nursing home, and the JAGS comparison still reported measurable, if modest, skew against the national population, per the IMPACT Collaboratory. A finding drawn from the Cooperative should be read as representative in a broad sense, not as a census of every nursing home resident with dementia. A second limit concerns setting. As of a December 2025 notice, assisted living providers — communities that house many people with earlier-stage memory concerns rather than the more medically complex residents typical of skilled nursing — were still being newly recruited to join, according to an HCAM newsletter from December 10, 2025. That means findings drawn from the Cooperative today speak mainly to nursing home residents, not to the broader population of older adults with memory concerns living in assisted living or at home.
What dementia-specific research is actually using this data?
One active project, known as NH-DDI, uses Cooperative data to build and test an algorithm that flags clinically significant drug-drug interaction risks among nursing home residents, including those with Alzheimer's disease and related dementias, with the goal of improving the decision-support software clinicians already use, according to AHCA's blog post on the Cooperative. That kind of tool matters because residents with dementia often take multiple medications and cannot always report side effects themselves. A second study, the STRIDE deprescribing trial, is led by investigators at the Joslin Diabetes Center and piloted in nursing homes in Michigan and Ohio.
It targets residents who have both diabetes and Alzheimer's disease or a related dementia, a group at elevated risk of dangerous low blood sugar from drugs like sulfonylureas. Its main measure of success is the share of these residents still on high-risk diabetes medications after six months, according to its ClinicalTrials.gov registration. For a family whose relative has both conditions, this trial is testing whether a more cautious medication approach can be made standard practice in nursing homes.
Can researchers connect this to other medical records, and what does that enable?
Approved researchers can link Cooperative records to Medicare claims data through the NIA Data LINKAGE Program, which requires an online application. This matters because it lets a single study combine the Cooperative's day-to-day clinical detail with claims-based information such as prior diagnoses and billed outcomes, according to AHCA's overview of the Cooperative.
For dementia research specifically, that combination is what makes a study like the drug-interaction algorithm or the STRIDE trial possible in the first place — neither data source alone would show both the clinical event and its downstream billed outcome. A family member reading about a dementia-drug study drawn from this pipeline can reasonably expect the findings to rest on actual medication administration records rather than inferred prescribing patterns.
What this means if you're tracking a loved one's dementia care
These studies are research tools, not clinical guidance you can act on directly, but they point to where better evidence is likely to come from in the near term:.
- Medication safety for people with dementia and co-occurring conditions (like diabetes) is an active research priority, not a settled area — the STRIDE trial's results are still pending.
- Drug-interaction checking tools used in nursing homes are being refined using real resident data, which may improve the software clinicians rely on, per AHCA's blog post.
- Findings drawn from this data currently apply most directly to nursing home residents; conclusions about earlier-stage dementia in assisted living or home settings should be treated with more caution given the Cooperative's current enrollment, per the HCAM newsletter.
- If a study claims a nationally representative finding, check whether it's a Cooperative-based study (which has already undergone the JAGS comparability check) or a smaller, single-site study.
You Might Also Like
- UAS-CLEAR Dementia Care Research Data Priorities in 2026: Study Design and Evidence Limits for Adults With Memory Concerns
- The $100 Million PROTECT-Cog Alzheimer’s Study Announced in 2026: Why the Findings May Not Change Care Yet for Adults With Memory Concerns
- Home-Based Dementia Care Research Priorities in 2026: What the Report Means for Adult Children
